Log In

GET A PIECE OF CANCERVAX

A Breakthrough Universal Cancer Vaccine

CancerVAX is a pre-clinical, pre-revenue biotech company developing a universal cancer vaccine that uses the body's immune system to fight cancer.

This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$348,402 Raised

Offering Circular | Selected Risks Related to this Offering | SEC EDGAR Page


REASONS TO INVEST


  • According to the World Health Organization, cancer is the second leading cause of death globally. Cancer vaccines, also known as cancer immunotherapies, are some of the latest weapons designed to fight cancer. CancerVAX treatments will be formulated to use the body’s own immune system to fight cancer, usually with milder side effects and more targeted than existing treatments, such as chemotherapy. The cancer immunotherapy market is expected to grow to $196 billion by 2030 (according to Bloomberg Business).*


  • The company has two research programs with a team of MDs and PhDs at the renowned cancer center at UCLA: (1) a novel universal cancer vaccine targeting multiple cancers, and (2) a single disease immunotherapy targeting Ewing sarcoma, a rare but deadly cancer that primarily affects young children. CancerVAX has exclusive rights to license any intellectual property and technology (patents) that may result from the research. UCLA is a top-ranked university known for its cancer research and medical school.


  • CancerVAX is headed by CEO Ryan Davies, who has an extensive background in the biotech industry including co-founding several biotech companies including, a nitric oxide topical wound-care company (Advanox), a medical device company (Purgo Scientific), and an antibiotic drug development company (Curza).


  • CancerVAX has previously raised $2 million of seed funding.


*source


THE Pitch


Detect. Mark. Kill.

CancerVAX is developing a universal cancer vaccine (currently in the conceptual testing stage) that will use the body’s immune system to fight off cancer. This process, known as cancer immunotherapy, is a state-of-the-art treatment that the company believes will detect, mark, and kill only cancer cells, while leaving the healthy cells alone.


CancerVAX’s research is performed by an experienced team of MDs and PhDs at UCLA. The company has two research agreements with UCLA as well as an option agreement, granting CancerVAX the exclusive rights to license all intellectual property and technology (patents) developed under the research agreements.

CancerVAX is headed by CEO Ryan Davies, who has an extensive background in the biotech industry including co-founding several biotech companies including a nitric oxide topical wound-care company product (Advanox), a medical device company (Purgo Scientific), and an antibiotic drug development company (Curza).

THE Problem & our solution


Get Better, Without Feeling Worse


Cancer is the second leading cause of death in the world – responsible for 10 million deaths in 2020 alone. (Source) Even in the U.S., 1.8 million new cases of cancer were diagnosed in just that one year. (Source)

However, cancer treatments still haven’t progressed past the options of surgery, chemotherapy, and radiation, which have extreme, life-long side effects. In addition to being toxic and harmful, treatments like chemotherapy can be expensive, and difficult for most people to afford.


A Universal Cancer Vaccine


CancerVAX is developing a universal cancer vaccine that targets multiple types of cancer and improves the recovery process. Much like how the COVID-19 vaccine trains the body to recognize and destroy coronavirus, CancerVAX’s vaccine would similarly leverage the body’s immune system to detect, mark, and kill cancer cells.


Most immunotherapy treatments kill bad cancer cells while also killing good, healthy cells simply because the natural cell markers they use as targets appear on both cancer and healthy cells. CancerVAX’s universal cancer vaccine would force cancer cells to reveal a unique marker, so they can be targeted and killed with a high level of precision, while leaving the healthy cells intact. CancerVAX believes this new method of targeting and destroying cancer with the body’s own immune system will treat cancer in a safe, non-toxic, and most importantly, highly targeted way.


Treating Kid’s Cancer - Ewing sarcoma


CancerVAX is also developing a disease-specific immunotherapy targeted at treating Ewing sarcoma, a rare but deadly bone and soft tissue cancer that primarily affects children and young adults, and for which there is no current FDA approved treatment for recurrence. 


The company has entered into a sponsored research agreement with the University of California at Los Angeles (UCLA) to develop effective immunotherapies, such as CAR T-cell and monoclonal antibodies, for Ewing sarcoma. 

THE market & our traction


A Never-Ending Need


Currently, over 100 types of cancers exist. In 2015 approximately $183 billion was spent on cancer health care, in the U.S. alone; that number is projected to grow to $246 billion by 2030. (Source)

CancerVAX raised an initial seed round of $2 million and has rights to three patent applications surrounding Universal Cancer Vaccine and Ewing sarcoma technologies. The company also has exclusive rights to license new intellectual property that is developed under the two CancerVAX research programs with UCLA, which offers other potential revenue streams.

why invest


Let's Beat Cancer


Pharmaceutical research is booming from the effects of the COVID-19 pandemic, where the medical community learned how to use mRNA to recognize and fight specific disease states. A similar concept is being applied by CancerVAX to create a vaccine with the purpose of using a patient’s immune system to detect, mark, and kill cancer.


The CancerVAX business model involves partnering with experienced cancer research institutions, like UCLA, to develop new life-changing drugs, followed by future plans to license or sell the company’s drugs, or license technologies to major pharmaceutical companies. 


As a biotech company, CancerVAX’s goal is to create value for our company and our shareholders with every step of incremental success we make on the path to FDA approval. From discovery, to optimization, to pre-clinical trials, and additional future phases (phase 1 clinical trials, phase 2 clinical trials, phase 3 clinical trials), every step is a value inflection point that CancerVAX believes could increase the company’s value and bring them one step closer to curing cancer.


Join CancerVAX and invest in its breakthrough technologies to help beat cancer!



AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.


THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.


CROWDCHECK VERIFIED REPORT CAN BE FOUND HERE.


THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

ABOUT

HEADQUARTERS
351 Paseo Nuevo, Floor 2
Santa Barbara, CA 93101

CancerVAX is a pre-clinical, pre-revenue biotech company developing a universal cancer vaccine that uses the body's immune system to fight cancer.

TEAM

Ryan Davies

Ryan Davies

Chief Executive Officer

Ryan has had a successful career as an entrepreneur, business executive, and public servant. Prior to joining CancerVAX, Ryan co-founded several biotech companies/technologies including a nitric oxide topical wound-care product, a medical device company (drug delivery system), and an antibiotic development company. Ryan served as CEO of Curza, a small molecule therapeutics company focused on developing new antibiotics; SVP at Clarke Capital Partners, a private growth equity investment firm; co-founder of a software/eCommerce company Found.com (acquired by CRS Retail Systems); co-founder of a software company O2 Blue (acquired by Prebon Yamane). His public service activities include serving on the Draper City Council (Utah) and serving on the campaigns of two U.S. presidential campaigns, one U.S. senate campaign, and two gubernatorial campaigns. Ryan holds degrees in Business Management from Ricks College and Political Science from Brigham Young University.

Byron Elton

Byron Elton

Chief Marketing Officer

Mr. Elton is an experienced media and marketing executive with a proven record in pioneering and new business development strategies and building top-flight marketing organizations. From 2018 through 2021 he was President of Elton Enterprises, Inc., which is involved in the wellness, fitness and health sectors. President & CEO of Carbon Sciences, Inc. a cleantech company developing technology to convert earth destroying carbon dioxide into a useful form; Senior Vice President of Sales for Univision Online; as Regional Vice President of Sales at AOL Media Networks; Senior Vice President of e-commerce for AOL Canada; has broadcast media experience with the ABC affiliate in Santa Barbara, CA and the CBS affiliate in Monterrey, CA; and served as President of the Alaskan Television Network. Mr. Elton studied Advertising and Marketing Communications at Brigham Young University.

TERMS

CancerVax
Overview
PRICE PER SHARE
$2
DEADLINE
May 31, 2024
VALUATION
$61.02M
FUNDING GOAL
$500 - $10M
Breakdown
MIN INVESTMENT
$500
MAX INVESTMENT
$1,000,000
MIN NUMBER OF SHARES OFFERED
250
MAX NUMBER OF SHARES OFFERED
5,000,000
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum number of shares offered subject to adjustment for bonus shares. See bonus info below.

Investment Incentives and Bonuses*

Amount-Based:

Tier 1 | $5,000+

Invest $5,000+ and receive 5% bonus shares.

Tier 2 | $10,000+

Invest $10,000+ and receive 7% bonus shares.

Tier 3 | $25,000+

Invest $25,000+ and receive 10% bonus shares.

Tier 4 | $50,000+

Invest $50,000+ and receive 15% bonus shares.

Tier 5 | $100,000+

Invest $100,000+ and receive 20% bonus shares.

The 10% StartEngine Owners' Bonus

CancerVax will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $2.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $2.00. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested (if any). Eligible investors will also receive the Owner’s Bonus in addition to the amount based bonus.

*All perks occur when the offering is completed.

NEW UPDATES

09.22.23

IMPORTANT CEO UPDATE About Bonus Shares

Ryan Davies, CEO of CancerVAX, recently thanked investors and urged everyone to take advantage of valuable investor perks. 

With up to 30% bonus CancerVAX shares available, the more an investor commits, the larger discount awarded in the form of bonus shares!

“Our investors are family to us and we want them to earn bonus shares which is why we have made it straightforward and easy,” Ryan stated.

 “We created 5 tiers that allow each investor to pick a level that works for them,” Ryan explained, “and earn valuable bonus shares with as little as a $500 investment by being a StartEngine Owner’s Bonus member, which awards 10% bonus shares.”

CancerVAX is revolutionizing cancer treatment using the body's immune system to fight cancer.

Amount-Based Bonus Shares:

  • Tier 1 | Invest $5,000+ and receive 5% bonus shares.
  • Tier 2 | Invest $10,000+ and receive 7% bonus shares.
  • Tier 3 | Invest $25,000+ and receive 10% bonus shares.
  • Tier 4 | Invest $50,000+ and receive 15% bonus shares.
  • Tier 5 | Invest $100,000+ and receive 20% bonus shares.

10% StartEngine Owners' Bonus + Amount-Based Bonus Shares = Up to 30% Bonus Shares.

Each week our research teams make progress in their mission.

We invite you to join us and earn some BONUS SHARES.

Help us in the fight against cancer by investing in CancerVAX.

For more information about CancerVAX, please visit https://www.cancervax.com

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

09.21.23

HOPE FOR PEDIATRIC CANCER



There may be hope for pediatric cancer on the horizon as scientists move ever closer to a treatment for Ewing sarcoma, a pervasive and difficult-to-treat cancer that attacks bones and soft tissue, more common in teens and young adults over any other age group.  

Recently, the research team found the silver bullet: a protein biomarker present on most Ewing sarcoma tumors.  Now, they’re targeting that biomarker in the quest to help cancer patients’ immune systems recognize, attack and destroy Ewing sarcoma.

In collaboration with a team of researchers and physicians at UCLA, CancerVAX has been working on developing treatments for Ewing sarcoma.  It all started with the identification of a common protein biomarker present on the surface of more than 90% of Ewing sarcoma tumors.  

This work is giving rise to treatments that will help spur cancer patients’ own immune systems into action to fight against this otherwise difficult-to-terminate cancer.  The treatments could enter early testing phases as early as Spring 2024.

For patients fighting Ewing sarcoma, any step forward towards a new viable treatment is a positive one.  And for the youngest of these, it could mean a new opportunity to live free from the tubes, needles and stress of cancer, and to live strong within their own bodies.


For more information about CancerVax, please visit https://www.cancervax.com

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

PRESS

Article Image
HealthLeaders

CANCERVAX CEO SEES A HOME RUN WITH BREAKTHROUGH

Article Image
HealthCare Business Today

Scientists Have Found A Silver Bullet For Pediatric Cancer

Article Image
LabioTech

Sarcoma research: is a breakthrough in sight?

ALL UPDATES

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into CancerVax.

$500

StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.

$5,000

Tier 1

Invest $5,000+ and receive 5% bonus shares.

$10,000

Tier 2

Invest $10,000+ and receive 7% bonus shares.

$25,000

Tier 3

Invest $25,000+ and receive 10% bonus shares.

$50,000

Tier 4

Invest $50,000+ and receive 15% bonus shares.

$100,000

Tier 5

Invest $100,000+ and receive 20% bonus shares.

JOIN THE DISCUSSION

0/2500

RN
Richard Negvesky

2 months ago

Is the methodology based upon mRNA technology?

1

0













CF
Christopher Flowers

3 months ago

I need to see links to the relevant 3 patents you say you hold before deciding whether to invest in this project. As a cancer specialist who has worked at UCLA and UCSF I need more information to complete due diligence

1

1













Aa
Al asparisi@gmail.com

3 months ago

I concur with other commenting on the Valuation. If the valuation of $60M made any sense, VC's would have jumped on this like pigs in a mud puddle. This company has nothing but a pipe dream. I could have made up the same pipe dream. Here let's try this: Let's solve Heart disease by creating a "vaccine" that eats cholesterol build up in your arteries. Am I now worth $60M ?? The only worth this company has now, is it's research into Ewing Sarcoma's. Any investor should be aware that if this company is successful, it will be a decade or more. So be aware that there is a 95% chance you will lose 100% of your investment. With that said, I hope companies like this are successful, but the risk reward, especially at this valuation, is not for me.

1

0













TS
Timothy Shroyer

3 months ago

A $61MM valuation - pre-clinical and pre-revenue? C'mon guys. This is ridiculous. This is going to be an extremely long haul. You should be at $5-10MM.

0

0

FE
Francis Erdman

3 months ago

A friend's mother passed from pancreatic cancer a few years ago and as a "hail Mary" shortly before her death they did immunotherapy which had no impact - more recently, this same friend of mine had a friend who died of melanoma, after, again, a failed "hail Mary" of immunotherapy. Those are just two anecdotes I know of, but in general immunotherapy seems like a last ditch money waster by people in late stage cancer - if it were me, I'd skip the pointless therapies and let that money go to my heirs, rather than trying experimental stuff right down to the last minute. That's a personal decision obviously but the point is, immunotherapy does not work, has never worked, and this is really just Elizabeth Holmes territory trying to profit from guillable investors and/or desperate cancer patients, to be blunt. Probably why it does not work is the immune system largely evolved to fight nucleic-acid based pathogens (so, viruses, bacteria) but disease causing agents that are not nucleic-acid based (prions, for example), the immune system just isn't experienced enough to handle - and same with cancer - by definition it is not a foreign agent (like a virus) it is simply the body's own cells running amuk - the immune system cannot handle that, just as my portfolio cannot handle Theranos II, thank you.

1

0













JH
Justin Horvath

4 months ago

Hi, Why are you worth $60 million when you don’t even have a drug developed? In addition, I am assuming you haven’t even done any testing on said drug to see if it works, since of course it’s not developed. For a point of reference, Oncolyze another cancer biotech company on this platform, values themselves at $30 million and has a developed drug OM-301, which was declared orphan drug status by FDA. In addition they done some testing on it for its efficacy in animals. So why are you worth more when it seems you have done so less? Is there something I am missing here?

0

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

RAISED
$348,402
INVESTORS
242
MIN INVEST
$500
VALUATION
$61.02M

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.

www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.
Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRASIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.
By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information

(800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.

StartEngine Marketplace

The availability of company information does not indicate that the company has endorsed, supports, or otherwise participates with StartEngine.

None of the information displayed on or downloadable from www.startengine.com (the 'Website') represents a recommendation, offer, or solicitation of an offer to buy or sell any security. It also does not constitute an offer to provide investment advice or service. StartEngine does not (1) make any recommendations or otherwise advise on the merits or advisability of a particular investment or transaction, or (2) assist in the determination of fair value of any security or investment, or (3) provide legal, tax, or transactional advisory services.

All investment opportunities are based on indicated interest from sellers and will need to be confirmed.

Investing in private company securities is not suitable for all investors. An investment in private company securities is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities. Each investment also carries its own specific risks, and you should complete your own independent due diligence regarding the investment. This includes obtaining additional information about the company, opinions, financial projections, and legal or other investment advice. Accordingly, investing in private company securities is appropriate only for those investors who can tolerate a high degree of risk and do not require a liquid investment.

StartEngine Marketplace (“SE Marketplace”) is a website operated by StartEngine Primary, LLC (“SE Primary”), a broker-dealer that is registered with the SEC and a member of FINRA and the SIPC. StartEngine Bulletin Board ("SE BB") is a bulletin board platform that advertises interest in shares of private companies that previously executed Reg CF or Reg A offerings. SE BB enables shareholders to communicate interest in potential sales of shares in private companies and investors to discover, review, and potentially invest in private companies. As a bulletin board platform, SE BB provides a venue for investors to access information about private company offerings and connect with potential sellers. SE BB is distinct and separate from StartEngine Secondary (“SE Secondary”), which is an SEC-registered Alternative Trading System (ATS) operated by SE Primary. SE Secondary facilitates the trading of securities by matching orders between buyers and sellers and facilitating executions of trades on the platform. While a security may be displayed on the bulletin board, these securities will be subject to certain restrictions which may prevent the ability to buy and sell these securities in a timely manner, if at all. Even if a security is qualified to be displayed on the bulletin board, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.